

SQSTM1 (p62) Antibody (C-term) Blocking peptide
Synthetic peptide
Catalog # BP2183b**Specification**

SQSTM1 (p62) Antibody (C-term) Blocking peptide - Product InformationPrimary Accession [Q13501](#)**SQSTM1 (p62) Antibody (C-term) Blocking peptide - Additional Information****Gene ID** 8878**Other Names**

Sequestosome-1, EBI3-associated protein of 60 kDa, EBIAP, p60, Phosphotyrosine-independent ligand for the Lck SH2 domain of 62 kDa, Ubiquitin-binding protein p62, SQSTM1, ORCA, OSIL

Target/Specificity

The synthetic peptide sequence used to generate the antibody [BP2183b](#) was selected from the C-term region of human SQSTM1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

SQSTM1 (p62) Antibody (C-term) Blocking peptide - Protein Information**Name** SQSTM1 {ECO:0000303|PubMed:16286508, ECO:0000312|HGNC:HGNC:11280}**Function**

Molecular adapter required for selective macroautophagy (aggrephagy) by acting as a bridge between polyubiquitinated proteins and autophagosomes (PubMed:[15340068](http://www.uniprot.org/citations/15340068), PubMed:[15953362](http://www.uniprot.org/citations/15953362), PubMed:[16286508](http://www.uniprot.org/citations/16286508), PubMed:[17580304](http://www.uniprot.org/citations/17580304), PubMed:[20168092](http://www.uniprot.org/citations/20168092), PubMed:[22017874](http://www.uniprot.org/citations/22017874), PubMed:[22622177](http://www.uniprot.org/citations/22622177), PubMed:[24128730](http://www.uniprot.org/citations/24128730), PubMed:[28404643](http://www.uniprot.org/citations/28404643), PubMed:[29343546](http://www.uniprot.org/citations/29343546), PubMed:[29343546](#)

href="http://www.uniprot.org/citations/29507397" target="_blank">29507397, PubMed:31857589, PubMed:33509017, PubMed:34471133, PubMed:34893540, PubMed:35831301, PubMed:37306101, PubMed:37802024). Promotes the recruitment of ubiquitinated cargo proteins to autophagosomes via multiple domains that bridge proteins and organelles in different steps (PubMed:16286508, PubMed:20168092, PubMed:22622177, PubMed:24128730, PubMed:28404643, PubMed:29343546, PubMed:29507397, PubMed:34893540, PubMed:37802024). SQSTM1 first mediates the assembly and removal of ubiquitinated proteins by undergoing liquid-liquid phase separation upon binding to ubiquitinated proteins via its UBA domain, leading to the formation of insoluble cytoplasmic inclusions, known as p62 bodies (PubMed:15911346, PubMed:20168092, PubMed:22017874, PubMed:24128730, PubMed:29343546, PubMed:29507397, PubMed:31857589, PubMed:37802024). SQSTM1 then interacts with ATG8 family proteins on autophagosomes via its LIR motif, leading to p62 body recruitment to autophagosomes, followed by autophagic clearance of ubiquitinated proteins (PubMed:16286508, PubMed:17580304, PubMed:20168092, PubMed:22622177, PubMed:24128730, PubMed:28404643, PubMed:37802024). SQSTM1 is itself degraded along with its ubiquitinated cargos (PubMed:16286508, PubMed:17580304, PubMed:37802024). Also required to recruit ubiquitinated proteins to PML bodies in the nucleus (PubMed:20168092). Also involved in autophagy of peroxisomes (pexophagy) in response to reactive oxygen species (ROS) by acting as a bridge between ubiquitinated PEX5 receptor and autophagosomes (PubMed:26344566). Acts as an activator of the NFE2L2/NRF2 pathway via interaction with KEAP1: interaction inactivates the BCR(KEAP1) complex by sequestering the complex in inclusion bodies, promoting nuclear accumulation of NFE2L2/NRF2 and subsequent expression of cytoprotective genes (PubMed:20452972, PubMed:28380357, PubMed:33393215, PubMed:37306101). Promotes relocalization of 'Lys-63'-linked ubiquitinated STING1 to autophagosomes (PubMed:29496741). Involved in

endosome organization by retaining vesicles in the perinuclear cloud: following ubiquitination by RNF26, attracts specific vesicle-associated adapters, forming a molecular bridge that restrains cognate vesicles in the perinuclear region and organizes the endosomal pathway for efficient cargo transport (PubMed:27368102, PubMed:33472082). Sequesters tensin TNS2 into cytoplasmic puncta, promoting TNS2 ubiquitination and proteasomal degradation (PubMed:25101860). May regulate the activation of NFKB1 by TNF-alpha, nerve growth factor (NGF) and interleukin-1 (PubMed:10356400, PubMed:10747026, PubMed:11244088, PubMed:12471037, PubMed:16079148, PubMed:19931284). May play a role in titin/TTN downstream signaling in muscle cells (PubMed:15802564). Adapter that mediates the interaction between TRAF6 and CYLD (By similarity).

Cellular Location

Cytoplasmic vesicle, autophagosome. Preautophagosomal structure. Cytoplasm, cytosol. Nucleus, PML body. Late endosome. Lysosome. Nucleus Endoplasmic reticulum. Cytoplasm, myofibril, sarcomere {ECO:0000250|UniProtKB:O08623}. Note=In cardiac muscle, localizes to the sarcomeric band (By similarity). Localizes to cytoplasmic membraneless inclusion bodies, known as p62 bodies, containing polyubiquitinated protein aggregates (PubMed:11786419, PubMed:20357094, PubMed:22017874, PubMed:29343546, PubMed:29507397, PubMed:31857589, PubMed:37306101, PubMed:37802024). In neurodegenerative diseases, detected in Lewy bodies in Parkinson disease, neurofibrillary tangles in Alzheimer disease, and HTT aggregates in Huntington disease (PubMed:15158159). In protein aggregate diseases of the liver, found in large amounts in Mallory bodies of alcoholic and nonalcoholic steatohepatitis, hyaline bodies in hepatocellular carcinoma, and in SERPINA1 aggregates (PubMed:11981755). Enriched in Rosenthal fibers of pilocytic astrocytoma (PubMed:11786419). In the cytoplasm, observed in both membrane-free ubiquitin-containing protein aggregates (sequestosomes) and membrane- surrounded autophagosomes (PubMed:15953362, PubMed:17580304). Colocalizes with TRIM13 in the perinuclear endoplasmic reticulum (PubMed:22178386). Co-localizes with TRIM5 in cytoplasmic bodies (PubMed:20357094). When nuclear export is blocked by treatment with leptomycin B, accumulates in PML bodies (PubMed:20168092) {ECO:0000250|UniProtKB:O08623, ECO:0000269|PubMed:11786419, ECO:0000269|PubMed:11981755, ECO:0000269|PubMed:15158159, ECO:0000269|PubMed:15953362, ECO:0000269|PubMed:17580304, ECO:0000269|PubMed:20168092, ECO:0000269|PubMed:20357094, ECO:0000269|PubMed:22017874, ECO:0000269|PubMed:22178386, ECO:0000269|PubMed:29343546, ECO:0000269|PubMed:29507397, ECO:0000269|PubMed:31857589, ECO:0000269|PubMed:37306101, ECO:0000269|PubMed:37802024}

Tissue Location

Ubiquitously expressed.

SQSTM1 (p62) Antibody (C-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

SQSTM1 (p62) Antibody (C-term) Blocking peptide - Images

SQSTM1 (p62) Antibody (C-term) Blocking peptide - Background

SQSTM1/p62 is an adapter protein which binds ubiquitin and may regulate the activation of NF κ B1 by TNF- α , nerve growth factor (NGF) and interleukin-1. This protein may play a role in titin/TTN downstream signaling in muscle cells, and may also regulate signaling cascades through ubiquitination. This protein is involved in cell differentiation, apoptosis, immune response and regulation of K(+) channels. SQSTM1/p62 also appears to play a role in macroautophagic removal of intracellular protein aggregates. Cellular depletion studies of SQSTM1/p62 have indicated a role for association with LC3 and aggregate proteins in order to facilitate normal formation of the autophagosome.

SQSTM1 (p62) Antibody (C-term) Blocking peptide - References

Seibenhener, M.L., et al., Mol. Cell. Biol. 24(18):8055-8068 (2004). Eekhoff, E.W., et al., Arthritis Rheum. 50(5):1650-1654 (2004). Brajenovic, M., et al., J. Biol. Chem. 279(13):12804-12811 (2004). Kuusisto, E., et al., J. Neuropathol. Exp. Neurol. 62(12):1241-1253 (2003). Johnson-Pais, T.L., et al., J. Bone Miner. Res. 18(10):1748-1753 (2003).